Efficacy and Biomarker Explanation on Resectable Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study aimed to explore the efficacy and biomarker explanation on resectable Non-Small
Cell Lung Cancer who treated with Atezolizumab plus platinum based chemotherapy.